Polyrizon Ltd. announced on August 20, 2026, that it has completed contracting with all five U.S. clinical sites for the NASARIX™ Allergy Blocker (PL-14) study. This milestone advances the first-in-human trial toward patient enrollment of up to 120 subjects assigned in a 1:1 ratio to receive either the treatment or an isotonic saline control. The multicenter, randomized, single-blind trial aims to evaluate efficacy and safety for seasonal allergic rhinitis, with primary endpoints focusing on mean daily reflective Total Nasal Symptom Scores over 14 days. Patient recruitment will align with relevant allergy seasons based on local pollen counts. Polyrizon is a development-stage biotech company specializing in innovative intranasal hydrogels.
